We guide stakeholders located in Flanders during the whole process of planning and application to a call topic. Any Flanders-based organisation can request advice from the NCP advisors free of charge.
Tips and tricks to write a good proposal as well as the steps of the evaluation process are elaborated in this video series on Proposal Writing under Horizon Europe (only for registered users).
NCP Flanders’ Infosheets offers a deep dive into specific issues and answer to frequently asked questions. Several of our infosheets can be of help for preparing your proposal.
Under certain conditions, NCP Flanders reviews draft project proposals according to the EU selection criteria. Stakeholders based in Flanders can request a proposal review but should be aware we have limited capacity. The earlier in the process you send us your request, the more likely we will be able to answer positively.
Does you organisation has a European Liaison Office? First check with your support office as they might offer proofreading services.
What do we offer? Feedback on your draft proposal according to the relevant evaluation criteria for call topics under Pillar II of Horizon Europe and under the Digital Europe programme.
Elements to take into account if you consider to send us a request for proposal review:
Support during the proposal stage is also offered for EIC Accelerator. Find out more here.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.